Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 in Relapsed or Refractory CLL/SLL
NCT06539182Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Apr 2024; status: recruiting.
02
Drugs
birelentinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06539182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539182.